Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

Lenalidomide gained Food and Drug Administration (FDA) approval for treatment of patients with relapsed or refractory multiple myeloma (MM) in combination with dexamethasone in June 2006. In April 2005, the FDA and patient advocacy groups requested an expanded access programme to both provide lenali...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chen, Christine, Reece, Donna E, Siegel, David, Niesvizky, Ruben, Boccia, Ralph V, Stadtmauer, Edward A, Abonour, Rafat, Richardson, Paul, Matous, Jeffrey, Kumar, Shaji, Bahlis, Nizar J, Alsina, Melissa, Vescio, Robert, Coutre, Steven E, Pietronigro, Dennis, Knight, Robert D, Zeldis, Jerome B, Rajkumar, Vincent
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2009
Assuntos:
Haematological Malignancy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2728892/
https://ncbi.nlm.nih.gov/pubmed/19545290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.07728.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados